Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 3/20 | 0.54 |
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600558 | 0.90 | ABL1 (0.68) | ABL1MAP4K1CYP3A4LRRK2JAK2 | |
| SCHEMBL2600545 | 0.89 | ABL1 (0.55) | ABL1MAP4K1HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL2600524 | 0.80 | ABL1 (0.58) | ABL1MAP4K1CYP3A4LRRK2JAK2 | |
| SCHEMBL2600560 | 0.80 | MAP4K1 (0.50) | ABL1MAP4K1CYP3A4 | |
| SCHEMBL2600534 | 0.79 | ABL1 (0.72) | ABL1MAP4K1CYP3A4LRRK2POLQ | |
| SCHEMBL2600564 | 0.79 | ABL1 (0.58) | ABL1MAP4K1HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL2112195 | 0.78 | ABL1 (0.60) | ABL1MAP4K1LRRK2JAK2JAK3 | |
| SCHEMBL2600535 | 0.78 | ABL1 (0.72) | ABL1MAP4K1CYP3A4LRRK2POLQ | |
| SCHEMBL2600556 | 0.77 | ABL1 (0.58) | ABL1MAP4K1CYP3A4LRRK2POLQ | |
| SCHEMBL2600532 | 0.77 | ABL1 (0.70) | ABL1MAP4K1LRRK2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158647-B2 | Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005356-A1 | SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS | PDXK, MAP3K4, PDPK1 | ABL1 862/4885MAP4K1 16/4885HCRTR1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.